|
The announcement was made after market hours yesterday, 16 August 2018.
Meanwhile, the S&P BSE Sensex was up 282.50 points, or 0.75% to 37,946.06.
On the BSE, 2,242 shares were traded in the counter so far compared with average daily volumes of 7,611 shares in the past two weeks. The stock had hit a high of Rs 1,777.35 and a low of Rs 1,745.80 so far during the day. The stock hit a 52-week high of Rs 1,823.40 on 3 August 2018. The stock hit a 52-week low of Rs 882.55 on 22 August 2017.
AstraZeneca Pharma India announced that it has received Import & Market permission for Olaparib (Lynparza) 100 mg and 150 mg tablets for treatment of ovarian and breast cancer in India by the Drug Controller General of India (DCGI) . The receipt of this permission paves way for the launch of Olaparib (Lynparza) in India.
AstraZeneca Pharma India reported net profit of Rs 3.22 crore in Q4 March 2018 as against net loss of Rs 9.56 crore in Q4 March 2017. Net sales rose 30.27% to Rs 150.73 crore in Q4 March 2018 over Q4 March 2017.
AstraZeneca Pharma India is the operating company covering manufacturing, sales and marketing activities. It has an innovative portfolio to address the unmet needs in non-communicable diseases such as diabetes, heart disease, cancer, asthma & COPD.
|